Akari Therapeutics Plc - ADR Live Share Price Today, Share Analysis and Chart

Name: Akari Therapeutics Plc - ADR: Is Infosys Ltd. worth buying?
Item: Akari Therapeutics Plc - ADR
Rating: 1.26500
Author: Trendlyne DVM scores

about

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transfor...

1.10 -0.03 (-2.65%)

75.00% Fall from 52W High

8,044

XNAS Volume

XNAS 14 Jul, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

10.0 / 100

Technically Neutral

40.6 / 100

No estimates available

Akari Therapeutics Plc - ADR Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Akari Therapeutics Plc - ADR Live Share Price Today, Share Analysis and Chart

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transfor...

75.00% Fall from 52W High

SWOT Analysis

Akari Therapeutics Plc - ADR Live Price Chart